Latest / Pharmacy Podcast Network / Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient | PTCE Pharmacy Connect
Transcript
- 0:07Speaker 1: You are listening to the Pharmacy Podcast Network.
- 0:19Speaker 2: Hello and welcome to ptce's Pharmacy Connect, a podcast focused
- 0:24Speaker 2: on continuing education created by pharmacists for pharmacists. PTC is
- 0:31Speaker 2: the leader in pharmacy and managed care education. In these episodes,
- 0:36Speaker 2: listeners will be presented with the most recent clinical updates
- 0:39Speaker 2: and strategies for implementing into practice and now Here's our
- 0:44Speaker 2: host and founder of the Pharmacy Podcast Network, Todd Yuri.
- 0:48Speaker 1: Welcome to this episode title Best Practices for Management of Hyperlipidemia,
- 0:53Speaker 1: a focus on guidelines and patient adherence. This activity is
- 0:58Speaker 1: jointly provided by the University of Connecticut School of Pharmacy,
- 1:02Speaker 1: Stores in Pharmacy Times Continuing Education, and is supported by
- 1:07Speaker 1: an educational grant from nov Artist Pharmaceuticals Corporation. The educational
- 1:12Speaker 1: objectives for today are as follows. Examine the best practices
- 1:17Speaker 1: for optimizing medication adherence and treatment initiation in hypercholesterolemia. Examine
- 1:24Speaker 1: best practices for optimizing medication adherents and treatment initiation in
- 1:29Speaker 1: hypercholesterol limia management. And to explain patient education in counseling
- 1:36Speaker 1: for managing hypercholesterolemia. Hey, welcome back to PTCEE Pharmacy Connect.
- 1:43Speaker 1: It's been too long. This is an amazing episode with
- 1:47Speaker 1: two people. I'm so glad I'm getting to work with
- 1:51Speaker 1: doctor Joseph Stein again. He's back. We were saying since
- 1:55Speaker 1: twenty twenty. It's been too long. This is the best
- 1:58Speaker 1: practices for management of hyperlipidemia, a focus on guidelines and
- 2:04Speaker 1: patient adherents. That's such an important topic. I'm great to
- 2:08Speaker 1: be back. I'm great to have PTCE back on the network.
- 2:11Speaker 1: They're leaders in pharmacy managed care education. In these episodes
- 2:15Speaker 1: are for our pharmacists, but we encourage physicians to be listening, collaborating,
- 2:19Speaker 1: coming up with questions, engage with PTCEE Pharmacy Connect on
- 2:24Speaker 1: social media as well. Heavy usage on LinkedIn and also Instagram.
- 2:29Speaker 1: Joe Cecine, it's so good to see you and be
- 2:32Speaker 1: back on PTSEE Pharmacy Connect.
- 2:35Speaker 3: How are you.
- 2:35Speaker 4: I'm doing great. Todd, it's great to work with you again.
- 2:38Speaker 1: Also, and we have a special guest. We have doctor
- 2:41Speaker 1: Mary Katherine chi Le and she's Executive Director Ambulatory Pharmacy
- 2:45Speaker 1: Services at Grady Health System from Atlanta, Georgia. It's great
- 2:50Speaker 1: to see you, Mary Catherine. How are you?
- 2:52Speaker 4: Yeah?
- 2:52Speaker 3: Thanks for having me.
- 2:54Speaker 1: All right, So, doctor Joe Sistine, who is a professor
- 2:58Speaker 1: and Associate Disease Dean for Clinical Affairs at the University
- 3:02Speaker 1: of Colorado and Shoots Medical Campus SAgs School of Pharmacy
- 3:07Speaker 1: and Pharmaceutical Sciences in Aurora, Colorado. Doctor Sascine will lead
- 3:13Speaker 1: in engaging in practical discussion on hyperlipidemia management, focusing on
- 3:17Speaker 1: evidence based strategies to optimize lipid lowering therapy and joining
- 3:22Speaker 1: us today as we just introduced doctor Cheley and a
- 3:26Speaker 1: podcaster to boot, So talk to me about that real
- 3:30Speaker 1: quick before we get started.
- 3:33Speaker 3: Yeah. I love it.
- 3:34Speaker 5: I love being able to talk to other people in
- 3:36Speaker 5: different professions and different specialties that I'm in and learn
- 3:39Speaker 5: all the different things that we do as pharmacists, how
- 3:41Speaker 5: we collaborate with other providers, or even just the patient
- 3:45Speaker 5: experience that we have. I think it makes us better
- 3:48Speaker 5: as pharmacists.
- 3:50Speaker 1: Joe, I'm kicking this over to you. You're going to
- 3:53Speaker 1: take us through this latest in hyperlipidemia management.
- 3:57Speaker 4: All righty, thank you Todd for passing a baton. I'm
- 3:59Speaker 4: really excited to be here again and to talk about
- 4:02Speaker 4: something I love, which is lipid management. Just to give
- 4:05Speaker 4: you a little bit further insight about my background. As
- 4:08Speaker 4: you introduced me, I am a professor and Associate dean
- 4:11Speaker 4: for Clinical Affairs at the University of Colorado. We're on
- 4:13Speaker 4: the Anshoots Medical Campus, but we're an integrated medical campus
- 4:18Speaker 4: where you have School of Medicine, College and nursing, dental medicine,
- 4:22Speaker 4: and other allied health professionals. In my day to day duties,
- 4:26Speaker 4: I have a lot of academic things that I do,
- 4:28Speaker 4: but one thing that I have a passion for is
- 4:31Speaker 4: cardiovascer disease, whether it be teaching students or practicing in
- 4:35Speaker 4: primary care managing patients to reduce their cardiovascular risk. Overall,
- 4:41Speaker 4: a lot of what I do comes back to lipid management,
- 4:43Speaker 4: so I do consider myself one of the lipid nerves.
- 4:46Speaker 4: As I know my colleague MK also would align herself
- 4:49Speaker 4: with too. It's my passion as a clinical pharmacist. I
- 4:53Speaker 4: really feel that managing hypercholesterol and may can help our
- 4:56Speaker 4: patients live longer and live healthier, and I'm just fortunate
- 5:00Speaker 4: that I have the ability to do that. As introduced,
- 5:03Speaker 4: I'm joined by my dear friend, doctor Mary Catherine Cheley.
- 5:06Speaker 4: I'll call her MK here forward. She'll be discussing this
- 5:10Speaker 4: topic along with me. Collectively, we're going to discuss a
- 5:13Speaker 4: whole bunch of different things, including best practices for optimizing
- 5:17Speaker 4: medication adherence, treatment initiation, patient education, and counseling for managing hypercholesterolaemia. MK.
- 5:25Speaker 4: Let me just pass it you to tell us a
- 5:26Speaker 4: little bit more about yourself.
- 5:28Speaker 3: Yeah, thank you guys for having me.
- 5:30Speaker 5: I love being here and Joe I love chatting with
- 5:33Speaker 5: you about our shared amazing experiences being lipid nerds. So
- 5:37Speaker 5: I am currently the executive Director of Ambulatory Pharmacy at
- 5:40Speaker 5: Grady Health System in Atlanta. My purview includes not only
- 5:44Speaker 5: our clinical services, but also our community pharmacies, our specialty pharmacies,
- 5:48Speaker 5: medication access, and medication adherents.
- 5:51Speaker 3: Before I stepped into.
- 5:52Speaker 5: That role, I was a clinical pharmamccist and primary care
- 5:56Speaker 5: where I was gifted lipids by someone who left and
- 5:59Speaker 5: I was like, man, lippets, No.
- 6:03Speaker 3: Like, lipids are so interesting.
- 6:05Speaker 5: So I definitely drank the lipid juice and totally loved
- 6:10Speaker 5: everything about lipid clinic. I still to this day will
- 6:13Speaker 5: go to clinic regardless of what's happening. Thursday mornings are
- 6:17Speaker 5: my day to go to my happy place and my
- 6:20Speaker 5: samee place to still see patients and clinic I will
- 6:23Speaker 5: never ever give it up. And that is how you
- 6:26Speaker 5: and I met Joe through the National Lipid Association. So
- 6:29Speaker 5: it has been so great to continue to kind of
- 6:31Speaker 5: see our profession grow and then to see within the
- 6:35Speaker 5: lipid space how pharmacists can fill that gap as therapeutics
- 6:38Speaker 5: have changed dramatically over the last fifteen years.
- 6:43Speaker 4: Absolutely never let go of that of that portion of
- 6:46Speaker 4: your job. And I'm so glad that we're colleagues and
- 6:48Speaker 4: that we both can help our patients and help our
- 6:50Speaker 4: communities by educating and implementing some practice model innovations. For
- 6:56Speaker 4: those of you who are listening, you probably notice that
- 6:58Speaker 4: there's three Pharmacy Times I'm ce webinars and they're really
- 7:01Speaker 4: excellent and they covered everything from the basics about hypercholesterollemia,
- 7:06Speaker 4: to new and emerging therapies for LDL cholesterol and even
- 7:09Speaker 4: LPA lowering, and one that focused in on the role
- 7:13Speaker 4: of the pharmacist some big take on points for me.
- 7:16Speaker 4: The first webinar really did a good job of going
- 7:19Speaker 4: over the landscape why it's important, why lipids will not
- 7:22Speaker 4: get old cardiovascar disease number one killer in the United
- 7:26Speaker 4: States for many many years in a row. It's not cancer,
- 7:29Speaker 4: though cancer is very important. It's cardiovascar disease. So all
- 7:33Speaker 4: we can do to mitigate our patient's risk of developing
- 7:36Speaker 4: cardiovask events is really important. And that first webinar really
- 7:39Speaker 4: set the stage and went over some of the basics
- 7:41Speaker 4: about lip of proteins and really told us that LDL
- 7:46Speaker 4: cholesterol remains our number one target because it's the aathrodenic
- 7:50Speaker 4: liper protein that we focus our attention on, as are
- 7:53Speaker 4: some other liper proteins too, But that, along with risk
- 7:57Speaker 4: factor management really came across louding career in that first webinar.
- 8:01Speaker 4: The second one was on treatment in particular LDL loring,
- 8:07Speaker 4: and I think a big take home message that I
- 8:09Speaker 4: got from that we have a lot of tools at
- 8:10Speaker 4: our disposal. We have statin based therapy which has been
- 8:13Speaker 4: around for very long period of time, which is our
- 8:15Speaker 4: standard of care. But heck, you know, this is not
- 8:18Speaker 4: a boring topics topic because there's plenty of nonstat and
- 8:21Speaker 4: add on agents to lower LDL cholesterol. Proven drugs like
- 8:24Speaker 4: a zidamibe, the PCSK nine inhibitors, whether it's in chlysserin,
- 8:28Speaker 4: which is a newer injection given on a maintenance schedule
- 8:32Speaker 4: every six months, or a monoclonal antibody. And we even
- 8:36Speaker 4: have some newer data with other oral agents like bempidotic acids.
- 8:41Speaker 4: So it really is fun and just getting a glimpse
- 8:43Speaker 4: into some of the things that are around the corner.
- 8:46Speaker 4: Not only for LDL loring. We'll have some new oral
- 8:48Speaker 4: therapies that our PCs can end blockers. We may have
- 8:51Speaker 4: some C TEP inhibitors, which are an older drug class
- 8:54Speaker 4: never came to fruition, but maybe hey, another one might
- 8:57Speaker 4: come soon. But also like a protein A or LPLA.
- 9:01Speaker 4: You hear a lot about that and there's emerging targets
- 9:04Speaker 4: for that. That was discussed in webinar two and the
- 9:07Speaker 4: third one really talked about practice implementation. So I'm going
- 9:11Speaker 4: to pass it back to you MK, since you know
- 9:13Speaker 4: about webinar quite three. What were some of your take
- 9:15Speaker 4: home points that you want to share with our audience.
- 9:18Speaker 5: Yeah, so that was the one that I was lucky
- 9:20Speaker 5: enough to have a role in, and mine was all
- 9:23Speaker 5: talking about the role of the pharmacist within nonstatin therapies.
- 9:27Speaker 5: We know that statin's are king, we know that they're
- 9:29Speaker 5: going to be here for a while.
- 9:30Speaker 3: But when we get.
- 9:31Speaker 5: Outside of that, we get into kind of where we
- 9:34Speaker 5: as pharmacists shine. So making sure that patients are on
- 9:38Speaker 5: clinically the right med we all know to start with statins,
- 9:41Speaker 5: but then what's next. We've got so many options now,
- 9:44Speaker 5: so which one is clinically the right one for the patient?
- 9:47Speaker 3: How do they have access to that?
- 9:49Speaker 5: Because while our providers and physicians and apps are amazing,
- 9:53Speaker 5: nurses do their best, no one is better than a
- 9:55Speaker 5: pharmacist at getting patients access to drugs. And we all
- 9:59Speaker 5: know that drugs only if you can take them, and
- 10:01Speaker 5: if you can't get them, you can't take them. And
- 10:04Speaker 5: then in addition to that, drugs continue to work, but
- 10:06Speaker 5: you got to keep swallowing it or injecting it. So
- 10:09Speaker 5: making sure that we have adequate medication adherents, and that's
- 10:12Speaker 5: what gets us really to that therapeutic objective that we
- 10:15Speaker 5: all want of lowering LDL cholesterol doesn't work without drugs.
- 10:19Speaker 5: You got to make sure that people have access to
- 10:21Speaker 5: the things that they need.
- 10:23Speaker 4: Our well stated you know, amia drugs don't work if
- 10:26Speaker 4: people don't take them, and we're there to help people,
- 10:29Speaker 4: but sort of to drive this home a little bit,
- 10:31Speaker 4: I want to share with you a challenging patient that
- 10:34Speaker 4: I encountered recently. And if this person doesn't come from
- 10:37Speaker 4: my particular practice, it's somebody I've consulted on for years.
- 10:41Speaker 4: It happens to be a retired pharmacist who I know
- 10:44Speaker 4: moderately well. So let me share this patient with you,
- 10:47Speaker 4: and I do want to get your insights MK. So
- 10:49Speaker 4: this patient I'm talking about, we'll call this person TJ.
- 10:53Speaker 4: He's in his upper sixties and he's had a long
- 10:55Speaker 4: standing history of hypercholesterolemia. He's also had hypertension and what
- 11:00Speaker 4: he calls pre diabetes, also is obeseis B is right
- 11:06Speaker 4: around thirty, though he feels he's fit. He does engage
- 11:10Speaker 4: in lifestyle modifications, but he drinks probably about ten to
- 11:13Speaker 4: twenty drinks a week, maybe a little bit more than
- 11:15Speaker 4: We'll be like, that's the picture of my patient TJ.
- 11:20Speaker 4: Now here's why I've interacted with him over the years
- 11:22Speaker 4: so frequently. He has had a challenge with taking statin therapy.
- 11:27Speaker 4: He was on lipid loorid therapy, tried what he says
- 11:30Speaker 4: more than three different statins, everything from daily statins in
- 11:35Speaker 4: moderate doses down the lower doses, even intermitted dosing using
- 11:39Speaker 4: rosuvistatin a couple times a week. And he tried that
- 11:42Speaker 4: for many many years ago when his cholesterol was just
- 11:45Speaker 4: hiden and to have as many comorbidities and he had a
- 11:48Speaker 4: problem with tolerability, so he ended up not on lipid
- 11:51Speaker 4: lorid therapy for many many years. Well, things changed with TJ. Recently.
- 11:55Speaker 4: He experienced an a schemic stroke. It was what he
- 11:58Speaker 4: called a minor stroke. So he has a lot of
- 12:00Speaker 4: actually residual function which is great. But his lipet panel
- 12:05Speaker 4: during that time of his stroke, his LDAL was one
- 12:07Speaker 4: hundred and sixty two milligrams. Protest laders HDL was thirty
- 12:10Speaker 4: eight tryglist whites were two fifteen. So he has that
- 12:13Speaker 4: metabolic picture along with his diabetes and obesity and non
- 12:17Speaker 4: on lipidoid therapy. So he's well insured. He has a
- 12:21Speaker 4: Medicare supplement and he decided to go back on rosuvastatin
- 12:26Speaker 4: and he tolerated a small amount five miligrams twice a week,
- 12:32Speaker 4: which is off label, and this provided some benefit. It
- 12:34Speaker 4: dropped his LDAL down to one twenty five. Now when
- 12:38Speaker 4: I look at TJ, he's asking me for advice, and
- 12:40Speaker 4: you know, this is not the kind of person I'm
- 12:42Speaker 4: going to get to go back on a high intensity
- 12:44Speaker 4: stat and it's just not going to happen in this person.
- 12:47Speaker 4: So I think about what are his goals of therapy?
- 12:49Speaker 4: So I had to remind him, and he knew this
- 12:51Speaker 4: pretty well that per ACC expert consensus decision pathway recommendations,
- 12:57Speaker 4: ideally really want that LDL clasterol to be less in
- 13:00Speaker 4: fifty five and we really want to drop is LDL
- 13:02Speaker 4: at least fifty percent. So we got a lot of
- 13:04Speaker 4: room for improvement. So what is evidence based as far
- 13:08Speaker 4: as recommendations thereafter? This is a person who is considered
- 13:11Speaker 4: very high risk because of his clinical ASCVD and his
- 13:14Speaker 4: other comorbidities, his high risk conditions, So there would be
- 13:19Speaker 4: value in evidence base and adding a zidamibe or maybe
- 13:22Speaker 4: using a piece as can I monoicle and I anibody
- 13:25Speaker 4: proven therapies on top of maximally tolerated stat and background
- 13:30Speaker 4: of which him it's very low intensity better than nothing,
- 13:33Speaker 4: but that's what we have, and there may be some
- 13:35Speaker 4: consideration used epidotica acid, perhaps in combination with something else,
- 13:40Speaker 4: since we do have some data on that it may
- 13:42Speaker 4: not reduce his LDL two less than fifty five. Though,
- 13:46Speaker 4: so I also also think come to mind some things
- 13:50Speaker 4: that this is the kind of patient because we've had
- 13:52Speaker 4: a problem with adherents that we do need to diligently
- 13:54Speaker 4: monitor him not only for a drop in LDL cholesterol,
- 13:58Speaker 4: but just to make sure he's on track, to make
- 14:00Speaker 4: sure he continues to take whatether we might implement. So,
- 14:03Speaker 4: as I mentioned, this person is matured with the Medicare
- 14:05Speaker 4: supplement plan. He also, as I did not mention, he
- 14:09Speaker 4: lives in the mountains, so he's not close to his
- 14:12Speaker 4: healthcare system, but he's integrated into a managed care, large,
- 14:16Speaker 4: robust health system which actually has clinical pharmacists that manage
- 14:19Speaker 4: medications quite well. And I guess, you know, just to
- 14:24Speaker 4: talk a little bit, we use this guy as a framework,
- 14:27Speaker 4: but because he came from a health system that had
- 14:30Speaker 4: integrated pharmacists, I do want to sort of talk a
- 14:33Speaker 4: little bit about these practice models. This person I'm consulting with,
- 14:36Speaker 4: but he's not part of my health system. But k
- 14:40Speaker 4: throughout your career, you really have you know, developed clinical
- 14:42Speaker 4: pharmacy programs and implemented evidence based treatments. So, in your opinion,
- 14:48Speaker 4: to share with us, what do you think are some
- 14:50Speaker 4: of the best practice models that incorporate sort of a
- 14:52Speaker 4: team based approach to managing chronic illnesses like Hypercholesterolamia.
- 14:57Speaker 5: Yeah, So this is one of my favorite time topics
- 15:00Speaker 5: because I love thinking about the patient being at the
- 15:03Speaker 5: center of everything that we do and having this team
- 15:06Speaker 5: around them that really gets to practice within their specialty area.
- 15:10Speaker 5: So much so that I'm actually wrapping up writing a
- 15:12Speaker 5: paper about this about multidisciplinary care within lipid management.
- 15:16Speaker 3: So this is very timely for the discussion.
- 15:20Speaker 5: But to me, kind of that multidisciplinary team includes a physician.
- 15:24Speaker 5: It does not have to be a cardiologist. I think
- 15:27Speaker 5: that is really important for us as pharmacists to understand
- 15:31Speaker 5: and to make sure that we're doing our best with
- 15:33Speaker 5: lipid care, to know that it doesn't have to be
- 15:35Speaker 5: a cardiologist. It can be an internist, it can be
- 15:37Speaker 5: an undocrinologist, it could be a women's health provider. Obviously,
- 15:42Speaker 5: a clinical pharmacist I think is best practice because we
- 15:46Speaker 5: can take that patient once the diagnosis has been made.
- 15:49Speaker 5: We don't diagnose I became a pharmacist, I did not
- 15:52Speaker 5: want to touch people.
- 15:53Speaker 3: So that is outside of what I do.
- 15:55Speaker 5: I am going to take that diagnosis and then treat them.
- 15:58Speaker 5: That is where we stay up in to kind of
- 16:01Speaker 5: what is happening with this patient. Then we monitor and
- 16:04Speaker 5: we adjust from there. So within multiple states there are
- 16:07Speaker 5: collaborative practice agreements where pharmacists have different levels that they
- 16:11Speaker 5: can do, either that's independent practice or within consultation with
- 16:14Speaker 5: the provider.
- 16:15Speaker 3: I think that's huge.
- 16:17Speaker 5: One thing that I think is continuing to grow for
- 16:19Speaker 5: us in our pharmacy practice is that community pharmacist role.
- 16:24Speaker 3: So making sure.
- 16:25Speaker 5: That we have traditional community pharmacists where we can do
- 16:29Speaker 5: Like you mentioned, I developed our medication Adherence Program at Grady.
- 16:33Speaker 5: Those are community pharmacists that are making sure that based
- 16:36Speaker 5: on clinical outcomes or for instance, our A one CS
- 16:40Speaker 5: at Goal, Nope, are they overdue for a refill, Let's
- 16:42Speaker 5: call that patient. Let's figure out what we can do
- 16:44Speaker 5: for that patient. The same is true in lipid management
- 16:48Speaker 5: and then also specialty pharmacists. So you mention those monoclonal
- 16:51Speaker 5: antibodies or in chlyserin, those are drugs that most insurance
- 16:56Speaker 5: companies may consider to be specialty type meds. We know
- 16:59Speaker 5: that specialty pharmacy models are really the gold standard. They
- 17:03Speaker 5: do that refel coordination, they do benefits investigation, and when
- 17:06Speaker 5: patients aren't integrated within a specialty pharmacy bonus points, it
- 17:11Speaker 5: fits within a health system as well. Because of that
- 17:14Speaker 5: access to everything, making sure that they have access to
- 17:18Speaker 5: their meds, they're more likely to actually fill it.
- 17:20Speaker 3: That is huge.
- 17:22Speaker 5: I also know that in that team based approach, lipids
- 17:25Speaker 5: are super important and meds are great, but you can
- 17:27Speaker 5: out eat a lot of meds, so we need to
- 17:29Speaker 5: make sure that we have a registered dietician nutritionist on board.
- 17:33Speaker 5: I think having nursing on board is hugely valuable, making
- 17:37Speaker 5: sure that they are that first touch point. When the
- 17:40Speaker 5: patient sends in an in basket message to the provider
- 17:43Speaker 5: or they call in, they're talking to a nurse. So
- 17:45Speaker 5: we need to make sure that that nurse is integrated
- 17:47Speaker 5: into our team as well as in certain cases we
- 17:50Speaker 5: need a genetic counselor we need an exercise specialist, we
- 17:53Speaker 5: need some of those other patients, other people in there.
- 17:56Speaker 5: And one that I think in our paper and in general,
- 17:59Speaker 5: that we really need to do a better job talking
- 18:01Speaker 5: about his behavioral health. So we know that when you
- 18:04Speaker 5: have a chronic illness, mental health is very important. Your
- 18:08Speaker 5: gentleman that you're talking about is drinking a little too much,
- 18:12Speaker 5: and yes, we can do that and we can talk
- 18:13Speaker 5: about that, but there is also real mental health conditions
- 18:18Speaker 5: that impact our physical health as well.
- 18:20Speaker 3: So making sure that we have.
- 18:21Speaker 5: Some type of behavioral health therapist or specialist involved is
- 18:25Speaker 5: really really important. Also making sure that if I was
- 18:30Speaker 5: this guy's provider, I would want to make sure that
- 18:33Speaker 5: we're making sure he has access to things. So not
- 18:36Speaker 5: just access in terms of prior authorization, but you mentioned
- 18:40Speaker 5: he lives in a mountain community, Like we got to
- 18:43Speaker 5: get drugs to him. I can't teleport things. That would
- 18:46Speaker 5: be great. We would save so much money on shipping
- 18:49Speaker 5: costs if we could teleport things, but we cannot right now.
- 18:52Speaker 5: So we need to make sure that we can get
- 18:54Speaker 5: him his drugs. And that's also something to think about.
- 18:57Speaker 5: You mentioned in Clisser and it's every six months, but
- 18:59Speaker 5: that's in the office. He's got to be able to
- 19:01Speaker 5: get there. And so making sure that we have broad
- 19:04Speaker 5: pharma coequity for all of our patients and making sure
- 19:08Speaker 5: that we're picking drugs that are evidence based and really
- 19:11Speaker 5: the best thing clinically and removing those barriers so that
- 19:15Speaker 5: they can get access to them, be it PA, transportation,
- 19:20Speaker 5: clinical trials, whatever that may be.
- 19:23Speaker 4: Hello, Louijah, I always love listening to you explain some
- 19:26Speaker 4: of this because you know, it puts it into perspective
- 19:28Speaker 4: and gives you know, credence and credibility to some of
- 19:31Speaker 4: the things that I think personally you've picked up on
- 19:34Speaker 4: a lot of the things that that are needed for
- 19:36Speaker 4: this patient TJ. And I am concerned about that alcohol
- 19:39Speaker 4: ingestion because you know, just overall looking at this patient,
- 19:42Speaker 4: I don't want to look at just the lip and
- 19:44Speaker 4: lens and say I want to fix your LDL. I
- 19:46Speaker 4: want to look at you holistically. He's cardiometabolic. I mean,
- 19:49Speaker 4: he's at risk for developing diabetes, which could make things
- 19:51Speaker 4: a whole bunch worse. The triglists, RIDES and HDL are
- 19:54Speaker 4: telling me, yeah, he probably does have a you need
- 19:56Speaker 4: more lifestyle, even though he considers himself relatively fit. But
- 20:01Speaker 4: I think some of the things that I also think
- 20:03Speaker 4: about is we used to have some taboos in pharmacy.
- 20:06Speaker 4: We'd say and you sort of said it too, and
- 20:09Speaker 4: I want to just explore this a little further. We
- 20:11Speaker 4: don't diagnose. In reality, we sort of do, right, We
- 20:15Speaker 4: identify patients. Yeah, and even I used to say we
- 20:18Speaker 4: never prescribe, but we do prescribe. And states are allowing
- 20:21Speaker 4: pharmacists to prescribe. Some of our crediting requirements are telling
- 20:26Speaker 4: us that we need to educate our students about diagnosing
- 20:28Speaker 4: and prescribing. So things change. And this is good because
- 20:31Speaker 4: we have our traditional roles. But you know, the practice
- 20:34Speaker 4: I work in, which is an interprofessional practice, we use
- 20:38Speaker 4: a collaborative practice agreement. We call them cbtms in Colorado,
- 20:41Speaker 4: and it allows us to start therapy. Well, you know,
- 20:44Speaker 4: we had sort of a project that we worked on
- 20:46Speaker 4: with one of our pharmacy residents, a second year resident,
- 20:49Speaker 4: and you know, for the past three months, we've been
- 20:51Speaker 4: prospectively looking for business, but business specifically in the lipet space.
- 20:56Speaker 4: We're prospectively identifying patients that are in care gaps. So
- 20:59Speaker 4: we started with high risk patients that have secondary prevention
- 21:02Speaker 4: status and looking to see us held L less and
- 21:04Speaker 4: fifty five. And we're implementing therapy and it's not always
- 21:07Speaker 4: starting a stat Most of our people already on a
- 21:10Speaker 4: stat and they may not be on enough, but we
- 21:11Speaker 4: have to think about these other things like nonstands, so
- 21:14Speaker 4: being proactive and using all the tools at our disposal,
- 21:17Speaker 4: and a CPA or a collaborative practice agreement really has
- 21:21Speaker 4: helped us beyond the aggressive because it allows us to
- 21:24Speaker 4: do a few things. It allows us to engage in
- 21:26Speaker 4: patient care to actually get our patients to their goals
- 21:29Speaker 4: to reduce their risk of future disease, but also allows
- 21:32Speaker 4: us to sort of showcase how we can improve the
- 21:35Speaker 4: patient care process. And one thing that we really do well,
- 21:40Speaker 4: I think our providers, whether they're physicians and nurse practitioners,
- 21:43Speaker 4: are pas, they look at us as being really good
- 21:47Speaker 4: with shared decision making, and shared decision making can be
- 21:50Speaker 4: sort of a scary word because you know, we don't
- 21:53Speaker 4: want to give up control as providers. But let's just
- 21:55Speaker 4: face it. You mentioned at MK who's in the center
- 21:58Speaker 4: of Let me just ask you, who'd you say is
- 22:00Speaker 4: in the center of the patient care team? The patient,
- 22:02Speaker 4: the passion. If they're not, nothing's going to happen, right.
- 22:08Speaker 4: So they're driving their own car, we're just you know,
- 22:11Speaker 4: we're helping them. Where the drivers assist or where you
- 22:13Speaker 4: know that annoying little little buzzers that come off that
- 22:16Speaker 4: tell you, you know, don't good. Yes, that's greatly, but
- 22:21Speaker 4: we can guide people. We're almost like Google Maps, which is,
- 22:25Speaker 4: you know, a form of artificial intelligence to help us
- 22:27Speaker 4: get to where we want to be. So we could
- 22:29Speaker 4: be those those patient advocates. But I think from a
- 22:32Speaker 4: shared decision making standpoint, one thing that from a sort
- 22:34Speaker 4: of a didactic standpoint, the American Heart Association put out
- 22:38Speaker 4: at the Shared Decision Making Framework recently was in twenty
- 22:41Speaker 4: twenty four. We've further shared decision making for a long time,
- 22:44Speaker 4: and we get scared, Oh you know, you know we
- 22:46Speaker 4: can't let the patient decide completely. Well, we need to.
- 22:49Speaker 4: We need to let the patient have some options and
- 22:51Speaker 4: let them decide. We have to give up on that
- 22:53Speaker 4: and say, yes, the patient does decide, we just need
- 22:55Speaker 4: to inform them. So these seven elements of shared decision making.
- 23:00Speaker 4: The first one is so important to me and if
- 23:02Speaker 4: I to scream out one. Information sharing is the first
- 23:06Speaker 4: part of shared decision making, and this is what we do.
- 23:08Speaker 4: We can share like with TJ, I can share insights
- 23:11Speaker 4: about what his disease is going to progress to if
- 23:13Speaker 4: we don't actually do a lot of cardiovascue risk production,
- 23:17Speaker 4: the truth about some of the medicines, some of the
- 23:19Speaker 4: newer ones, ones that have evidence, and if he's concerned
- 23:22Speaker 4: with inherents once they're more convenient. You mentioned access and
- 23:25Speaker 4: pharmacal equity, very important things. So there's a lot that
- 23:28Speaker 4: we can share that we have to translate into that
- 23:30Speaker 4: patient language. And that's the first element of shared decision making.
- 23:33Speaker 4: There's a few other really important ones, all more important.
- 23:36Speaker 4: Patient education, which you know is our way of translating
- 23:40Speaker 4: information into specific education on what to do differently lifestyle
- 23:44Speaker 4: wise or related to medicines. The third is laying out
- 23:48Speaker 4: the menu I call it, which is really exploring your
- 23:51Speaker 4: patient preferences, what are their goals, and tailoring our approach
- 23:54Speaker 4: to their goals so that we can actually meet them
- 23:56Speaker 4: in the middle and guide them as best we can.
- 23:59Speaker 4: Fourth is is something that a lot of people don't use,
- 24:03Speaker 4: which is really decision sport tools. I've had mixed success
- 24:07Speaker 4: depending on the person, but for the right person, actually
- 24:09Speaker 4: a decision support tool can be quite helpful. Do you
- 24:12Speaker 4: use decisions support tools in your practice? MK?
- 24:14Speaker 5: It depends on the patient, honestly, like you and I
- 24:17Speaker 5: have been doing this long enough that you can read
- 24:19Speaker 5: the patient and you're like, Okay, they're going to really
- 24:22Speaker 5: understand what a ten year risk is versus a lifetime
- 24:25Speaker 5: risk versus where you know.
- 24:27Speaker 3: They they don't care.
- 24:29Speaker 4: Yeah, no, they don't care.
- 24:29Speaker 3: They don't understand it. We need to do a little
- 24:31Speaker 3: more education on it.
- 24:32Speaker 4: Absolutely. That's why I like I've had mixed success because
- 24:34Speaker 4: some people are prepared for that and other people. I
- 24:36Speaker 4: work with some highly educated people the university, and they
- 24:38Speaker 4: want to know everything. They look at prediction models, all
- 24:40Speaker 4: those Yes, but actually the last three parts of this aha,
- 24:45Speaker 4: shared decision making framework are deliberation discussion really important, So
- 24:50Speaker 4: having your patient digest everything and you know, looking at
- 24:53Speaker 4: the pros and cons and you know, discussing that with
- 24:55Speaker 4: the patient so that they fully understand. And the key
- 24:57Speaker 4: here is if they're really bought into this, they'll comply
- 25:02Speaker 4: or adhere with their regimen. It hair is better than comply.
- 25:05Speaker 4: Comply means that, you know, derogatory, but adherence is really
- 25:09Speaker 4: a partnership because you want to get to this sixth element,
- 25:12Speaker 4: which is really a shared decision making agreement. What does
- 25:15Speaker 4: that mean? It's not just shared decision making. It's like
- 25:17Speaker 4: getting the verbal consent by your patient. That's their buy
- 25:20Speaker 4: and their commitment to get to their goals through the
- 25:23Speaker 4: tools that you're working with them to implement. And then lastly,
- 25:27Speaker 4: you don't let it go. With my patient TJ. I'm
- 25:31Speaker 4: going to have ongoing communication with him and I have
- 25:34Speaker 4: and review review success through monitoring and looking at objective
- 25:38Speaker 4: numbers of success. And speaking of this shared decision making model,
- 25:42Speaker 4: remember information sharing is really I think where we can
- 25:45Speaker 4: lean in quite a bit. So many medicines to use.
- 25:47Speaker 4: But I'll give you a little update on the patient TJ.
- 25:51Speaker 4: So he ended up actually going on a PCSK nine
- 25:53Speaker 4: monoclonal antibody, that's the one that was preferred by his
- 25:56Speaker 4: plan at the time, and after four weeks his l
- 26:00Speaker 4: deal went down to sixty seven milligrams per desth later
- 26:03Speaker 4: he was pretty pleased with that, encouraged by the production. Yeah,
- 26:06Speaker 4: it was this provider. You know, it might not be
- 26:09Speaker 4: where we want to be, but it's it's really it's
- 26:12Speaker 4: really good. Any comments MK from your Yeah, as far
- 26:16Speaker 4: as like giving patient choices, and we did with TJ
- 26:19Speaker 4: to some extent. I still think in the back of
- 26:21Speaker 4: my head, he's going to want the injection every six months.
- 26:24Speaker 4: He'll drive to Denver to get it because of it.
- 26:26Speaker 4: Inherent's round. But tell me a little bout what your
- 26:30Speaker 4: thoughts are.
- 26:31Speaker 5: Yeah, so sixty seven is awesome, and a lot of
- 26:34Speaker 5: my patients that is the motivation that they need to
- 26:38Speaker 5: keep going.
- 26:39Speaker 3: So I think that is huge.
- 26:40Speaker 5: I love that you and I are on opposite sides
- 26:42Speaker 5: of the country, but we still practice the.
- 26:44Speaker 3: Same and do the same things.
- 26:45Speaker 5: It's like one mind, Joe, We're so good at this.
- 26:49Speaker 5: So I think that is huge. I actually had a
- 26:52Speaker 5: patient just like this a couple of weeks ago in
- 26:54Speaker 5: clinic and she had had multiple strokes, so same kind
- 26:59Speaker 5: of picture. And you look at her dispense report, so
- 27:04Speaker 5: you look at her history, her phil history. She's on
- 27:07Speaker 5: Max Doo's Stanton but yet hasn't filled it in four months.
- 27:11Speaker 3: And she's like, oh, no, I take that one.
- 27:13Speaker 5: And I'm like, Okay, I believe you. I believe that
- 27:16Speaker 5: you take what you have. I don't think you have
- 27:18Speaker 5: this one. And so that information sharing back and forth
- 27:22Speaker 5: and that like, I'm not accusing you of not taking it.
- 27:25Speaker 5: I really think that you want to do the best.
- 27:28Speaker 5: You just don't have it, so it's my job to
- 27:30Speaker 5: make sure that you get it and make sure that
- 27:32Speaker 5: we get you what you need. Even still, so she
- 27:34Speaker 5: also has FH and her LDL was well over two fifty,
- 27:38Speaker 5: but neither here nor there, so we knew we were
- 27:40Speaker 5: going to have to do something else. We talked through
- 27:42Speaker 5: all the options, same thing. She picked the monoclonal antibody
- 27:47Speaker 5: she is. She was there with her mom, and so
- 27:50Speaker 5: her mom is like, okay, I'll inject.
- 27:52Speaker 3: I'll make sure that she gets this.
- 27:54Speaker 5: We talked about kind of the copay structure between the two,
- 27:57Speaker 5: so getting it filled through the pharmacy versus your medical
- 27:59Speaker 5: benefit and all those different things, and she was like, okay,
- 28:03Speaker 5: I want to try the self injections at home. I
- 28:05Speaker 5: think I'm going to see her in three months, and
- 28:08Speaker 5: we probably are going to have to switch to in
- 28:10Speaker 5: clysserin more than likely just because I just don't know
- 28:13Speaker 5: that she will be able to consistently get the injections.
- 28:17Speaker 3: But she wanted to try it. That was her decision
- 28:20Speaker 3: to make.
- 28:21Speaker 5: I made sure that we have close enough follow up,
- 28:23Speaker 5: so hey, we're not going to see you in six months,
- 28:25Speaker 5: We're going to see you in two to three because
- 28:28Speaker 5: I really need to get a handle on this, and
- 28:30Speaker 5: that was the decision that we made together. I hope
- 28:33Speaker 5: and hope that she is going to knock it out
- 28:36Speaker 5: of the park.
- 28:37Speaker 3: Her LDL is going to fall dramatically. That's going to
- 28:39Speaker 3: be great.
- 28:40Speaker 5: But I do think that there's so many different pieces
- 28:43Speaker 5: that we again as pharmacists, because we understand that access,
- 28:47Speaker 5: because we understand how how many patients do you have, Joe,
- 28:50Speaker 5: that don't know how to refill their meds, like they
- 28:53Speaker 5: think they need a new prescription every month, Like we're
- 28:58Speaker 5: in twenty twenty five, and we have people that don't
- 29:01Speaker 5: understand basic things that we take for granted. And so
- 29:05Speaker 5: that's where and our providers don't know either because they
- 29:07Speaker 5: just keep sending in new prescriptions. That poor pharmacist and
- 29:10Speaker 5: the community pharmacy is probably like, you gotta be kidding me, man,
- 29:14Speaker 5: let's figure this out. But those type of things I
- 29:17Speaker 5: think are really important to wrap up that shared decision making.
- 29:22Speaker 5: In terms of that review piece, it's not just we
- 29:25Speaker 5: made a decision, We're going to set.
- 29:26Speaker 3: It and forget it.
- 29:27Speaker 5: It's we need to come back to it, and that
- 29:29Speaker 5: what happened previously that previous decision then comes in to
- 29:33Speaker 5: inform our next decision, and we start the loop and
- 29:36Speaker 5: cycle all over again. We want to make sure that
- 29:40Speaker 5: we're not just setting and forgetting that our patients continue
- 29:43Speaker 5: to have that you know, loop back. Be it at
- 29:46Speaker 5: the community pharmacy, be it in the specialty space, which
- 29:48Speaker 5: again is why I cannot advocate enough for integrated pharmacies
- 29:52Speaker 5: within health systems because that information share is so much
- 29:56Speaker 5: easier between them.
- 29:57Speaker 3: But yeah, we have the same patients Joe I learned
- 30:00Speaker 3: to do.
- 30:01Speaker 4: I mean, yeah, I practice doesn't change, just changes settings,
- 30:05Speaker 4: but it doesn't change overall a whole bunch.
- 30:07Speaker 5: I'm going to guess my Southern diet is probably a
- 30:09Speaker 5: little bit worse than your Mountain diet.
- 30:12Speaker 4: Yeah, but we have that mountain beer and a whole
- 30:15Speaker 4: bunch of other things up here too, and it escapes nobody.
- 30:19Speaker 4: But before we wrap it up, I just really want
- 30:22Speaker 4: to talk about sort of a big ticket item, which
- 30:24Speaker 4: is really when we're promoting adherence, how do we actually
- 30:29Speaker 4: manage some of the costs of medicine Because some of
- 30:31Speaker 4: these great nonstant and drugs that work really well and
- 30:33Speaker 4: drop the old l significantly can be very costly and
- 30:37Speaker 4: I know you've let a lot of efforts in changing
- 30:40Speaker 4: your health systemic Grady to manage this. What are some
- 30:43Speaker 4: of the things that can share with us about you know,
- 30:45Speaker 4: your success in increasing affordability to me.
- 30:50Speaker 3: So, I think the first thing is to catch it
- 30:52Speaker 3: on the front end.
- 30:53Speaker 5: Patients lose motivation and patients lose that willingness to kind
- 30:58Speaker 5: of go the next step. If they get to the
- 31:00Speaker 5: pharmacy and see a bill of five hundred bucks even
- 31:04Speaker 5: well to do patients they're going to be like, man,
- 31:07Speaker 5: I don't know if that's worth it, like five hundred bucks.
- 31:10Speaker 5: So I think we need to be proactive in it.
- 31:13Speaker 5: So at Grady we used to have a process that
- 31:15Speaker 5: was nurse driven within the clinic, So making sure that
- 31:18Speaker 5: we prospectively figure out where these prayer offs are coming from.
- 31:21Speaker 5: Again prospectively when in Chliserin came out, making sure that
- 31:24Speaker 5: we're giving that patient that cost sharing information that they
- 31:26Speaker 5: have if it's Medicare is at twenty percent, and then
- 31:30Speaker 5: going back and doing our legwork first. So having an
- 31:34Speaker 5: integrated clinical pharmacist within the clinic. Hear me when I
- 31:39Speaker 5: say within the four walls of the clinic to me,
- 31:42Speaker 5: is best practice because we can go and talk to
- 31:44Speaker 5: that patient and say, hey, look, it's going to take
- 31:46Speaker 5: a couple of weeks. We are going to call you
- 31:48Speaker 5: and let you know what this looks like, or hey,
- 31:51Speaker 5: I already ran the test claim I can tell you
- 31:54Speaker 5: it's going to be forty five dollars or whatever it
- 31:56Speaker 5: may be, and then having an honest conversation about affordability
- 31:59Speaker 5: with the pain because it's not forty five dollars is
- 32:02Speaker 5: a lot for my patients. I work in an inner
- 32:04Speaker 5: city hospital that is really expensive, and they will have
- 32:08Speaker 5: to forego something else to pay forty five dollars, So
- 32:11Speaker 5: how do we continue to get that down and have
- 32:13Speaker 5: that honest conversation with them, which is a lot easier
- 32:16Speaker 5: to have in person than it is over the phone.
- 32:17Speaker 3: So then we can pick the right drug.
- 32:20Speaker 5: It may be that, hey, the copay for X drug
- 32:25Speaker 5: is three times what it is for WHY drug, and
- 32:28Speaker 5: we know that there are several exchange plans that have
- 32:30Speaker 5: that there's certainly things that an on site clinical pharmacist
- 32:34Speaker 5: can do to get them prescribing right in the first place.
- 32:36Speaker 3: So that's number one.
- 32:38Speaker 5: The second one to me is having a pharmacy driven
- 32:42Speaker 5: medication access department. So at our institution we have a
- 32:46Speaker 5: team of technicians, so one of them they're called medication
- 32:49Speaker 5: Access coordinators. They started in the patient assistance space, so
- 32:52Speaker 5: specifically with our uninsured patients and getting them access to
- 32:56Speaker 5: those manufacturer COE paid the manufacturer programs for uninsured payations.
- 33:01Speaker 5: Since then, we have realized that it's actually much easier
- 33:03Speaker 5: to get an uninsured patient drugs than it is to
- 33:05Speaker 5: get insured patient drugs oftentimes, so we created a separate
- 33:10Speaker 5: team just doing prior authorizations. We've taken over half the
- 33:13Speaker 5: HELL system so far. Our nurses could not be happier
- 33:16Speaker 5: to have us do their prior authorizations for them, but
- 33:20Speaker 5: we speak that pharmacy language. We want to make sure
- 33:24Speaker 5: that when we're giving that information back to the technician
- 33:27Speaker 5: on the insurer side, which then is going to send
- 33:29Speaker 5: it for clinical pharmacist review, that we use the right
- 33:32Speaker 5: words to under get to increase our ability to actually
- 33:35Speaker 5: get that prior approved. And then in addition to that,
- 33:39Speaker 5: making sure that we have technology support that we want
- 33:43Speaker 5: to make sure that all of those pas are flagged
- 33:46Speaker 5: or the patients don't leave without knowing that it's going
- 33:49Speaker 5: to take a minute to get it approved.
- 33:52Speaker 4: Well, that's awesome. I really appreciate you explaining sort of
- 33:55Speaker 4: how you do things and sort of those as you
- 33:57Speaker 4: as you're capturing, like some of the final thought I'll
- 34:00Speaker 4: just add a few things before we close here my
- 34:03Speaker 4: final thoughts. I think for those of you who are
- 34:05Speaker 4: pharmacists listening today's podcast, recognize that we can make a difference.
- 34:09Speaker 4: We can improve care through team based, integrated approaches that
- 34:13Speaker 4: really empower our patients, through shared decision making, patient ed
- 34:16Speaker 4: and providing clinical support the facilitate achievement of our therapeutic goals.
- 34:21Speaker 4: It has been a pleasure. Dr Mary Catherine Chile or
- 34:24Speaker 4: MK as I call you. Thank you for sharing your
- 34:27Speaker 4: thoughts today and how it can improve the quality and
- 34:30Speaker 4: maximize treatment outcomes for patients with hypercholesterolemia. It's been a
- 34:34Speaker 4: pleasure speaking with you and to our audience. Thank you
- 34:37Speaker 4: for listening and enjoy the rest of your day.
- 34:43Speaker 2: Thanks for tuning in to the PTCEE Pharmacy Connect podcast.
- 34:47Speaker 2: Your feedback is important to us. Please share with us
- 34:51Speaker 2: your thoughts on this episode and other topics you'd like
- 34:53Speaker 2: to learn about. Go to Pharmacytimes dot org forward flash contact.
- 35:00Speaker 2: That's the message